Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

Introduction: We previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ul...

ver descrição completa

Detalhes bibliográficos
Autores: Marques Pamies, Montserrat, Gil, Joan, Valassi, Elena, Hernández Meneses, Marta, Biagetti, Betina, Giménez Palop, Olga, Martínez, Silvia, Carrato, Cristina, Pons, Laura, Villar Taibo, Rocío, Araujo Castro, Marta, Blanco, Concepción, Simón, Inmaculada, Simó Servat, Andreu, Xifra, Gemma, Vázquez, Federico, Pavón, Isabel, García Centeno, Rogelio, Zavala, Roxana, Hanzu, Felicia A., Mora, Mireia, Aulinas, Anna, Vilarrasa, Nuria, Librizzi, Soledad, Calatayud, María, De Miguel, Paz, Álvarez Escolá, Cristina, Picó, Antonio, Sampedro, Miguel, Salinas, Isabel, Fajardo Montañana, Carmen, Cámara, Rosa, Bernabéu, Ignacio, Jordà, Mireia, Webb, Susan M., Marazuela, Mónica, Puig Domingo, Manuel
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/205747
Acesso em linha:https://hdl.handle.net/2445/205747
Access Level:acceso abierto
Palavra-chave:Acromegàlia
Somatostatina
Acromegaly
Somatostatin
id ES_1c8a3e8cf364e46251692358186ca430
oai_identifier_str oai:recercat.cat:2445/205747
network_acronym_str ES
network_name_str España
repository_id_str
spelling Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegalyMarques Pamies, MontserratGil, JoanValassi, ElenaHernández Meneses, MartaBiagetti, BetinaGiménez Palop, OlgaMartínez, SilviaCarrato, CristinaPons, LauraVillar Taibo, RocíoAraujo Castro, MartaBlanco, ConcepciónSimón, InmaculadaSimó Servat, AndreuXifra, GemmaVázquez, FedericoPavón, IsabelGarcía Centeno, RogelioZavala, RoxanaHanzu, Felicia A.Mora, MireiaAulinas, AnnaVilarrasa, NuriaLibrizzi, SoledadCalatayud, MaríaDe Miguel, PazÁlvarez Escolá, CristinaPicó, AntonioSampedro, MiguelSalinas, IsabelFajardo Montañana, CarmenCámara, RosaBernabéu, IgnacioJordà, MireiaWebb, Susan M.Marazuela, MónicaPuig Domingo, ManuelAcromegàliaSomatostatinaAcromegalySomatostatinIntroduction: We previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ultra-sensitive GH assays. We also studied the correlation of sAOT with tumor expression of E-cadherin and somatostatin receptor 2 (SSTR2) .Methods: A total of 47 patients treated with SRLs for 6 months were evaluated with the sAOT at diagnosis and correlated with SRLs' response. Those patients whose IGF1 decreased to <3SDS from normal value were considered responders and those whose IGF1 was >= 3SDS, were considered non-responders. The 2 hours GH value (GH2h) after s.c. administration of 100 mcg of octreotide was used to define predictive cutoffs. E-cadherin and SSTR2 immunostaining in somatotropinoma tissue were investigated in 24/47 and 18/47 patients, respectively.Results: In all, 30 patients were responders and 17 were non-responders. GH(2h) was 0.68 (0.25-1.98) ng/mL in responders vs 2.35 (1.59-9.37) ng/mL in non-responders (p<0.001). GH(2h) = 1.4ng/mL showed the highest ability to identify responders (accuracy of 81%, sensitivity of 73.3%, and specificity of 94.1%). GH(2h) = 4.3ng/mL was the best cutoff for non-response prediction (accuracy of 74%, sensitivity of 35.3%, and specificity of 96.7%). Patients with E-cadherin-positive tumors showed a lower GH(2h) than those with E-cadherin-negative tumors [0.9 (0.3-2.1) vs 3.3 (1.5-12.1) ng/mL; p<0.01], and patients with positive E-cadherin presented a higher score of SSTR2 (7.5 +/- 4.2 vs 3.3 +/- 2.1; p=0.01).Conclusion: The sAOT is a good predictor tool for assessing response to SRLs and correlates with tumor E-cadherin and SSTR2 expression. Thus, it can be useful in clinical practice for therapeutic decision-making in patients with acromegaly.Frontiers Media SA2024202420232024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion11 p.application/pdfhttps://hdl.handle.net/2445/205747Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.3389/fendo.2023.1269787Frontiers in Endocrinology, 2023, vol. 14https://doi.org/10.3389/fendo.2023.1269787cc by (c) Marques Pamies, Montserrat et al., 2023http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/2057472026-05-29T05:05:01Z
dc.title.none.fl_str_mv Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
title Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
spellingShingle Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
Marques Pamies, Montserrat
Acromegàlia
Somatostatina
Acromegaly
Somatostatin
title_short Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
title_full Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
title_fullStr Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
title_full_unstemmed Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
title_sort Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
dc.creator.none.fl_str_mv Marques Pamies, Montserrat
Gil, Joan
Valassi, Elena
Hernández Meneses, Marta
Biagetti, Betina
Giménez Palop, Olga
Martínez, Silvia
Carrato, Cristina
Pons, Laura
Villar Taibo, Rocío
Araujo Castro, Marta
Blanco, Concepción
Simón, Inmaculada
Simó Servat, Andreu
Xifra, Gemma
Vázquez, Federico
Pavón, Isabel
García Centeno, Rogelio
Zavala, Roxana
Hanzu, Felicia A.
Mora, Mireia
Aulinas, Anna
Vilarrasa, Nuria
Librizzi, Soledad
Calatayud, María
De Miguel, Paz
Álvarez Escolá, Cristina
Picó, Antonio
Sampedro, Miguel
Salinas, Isabel
Fajardo Montañana, Carmen
Cámara, Rosa
Bernabéu, Ignacio
Jordà, Mireia
Webb, Susan M.
Marazuela, Mónica
Puig Domingo, Manuel
author Marques Pamies, Montserrat
author_facet Marques Pamies, Montserrat
Gil, Joan
Valassi, Elena
Hernández Meneses, Marta
Biagetti, Betina
Giménez Palop, Olga
Martínez, Silvia
Carrato, Cristina
Pons, Laura
Villar Taibo, Rocío
Araujo Castro, Marta
Blanco, Concepción
Simón, Inmaculada
Simó Servat, Andreu
Xifra, Gemma
Vázquez, Federico
Pavón, Isabel
García Centeno, Rogelio
Zavala, Roxana
Hanzu, Felicia A.
Mora, Mireia
Aulinas, Anna
Vilarrasa, Nuria
Librizzi, Soledad
Calatayud, María
De Miguel, Paz
Álvarez Escolá, Cristina
Picó, Antonio
Sampedro, Miguel
Salinas, Isabel
Fajardo Montañana, Carmen
Cámara, Rosa
Bernabéu, Ignacio
Jordà, Mireia
Webb, Susan M.
Marazuela, Mónica
Puig Domingo, Manuel
author_role author
author2 Gil, Joan
Valassi, Elena
Hernández Meneses, Marta
Biagetti, Betina
Giménez Palop, Olga
Martínez, Silvia
Carrato, Cristina
Pons, Laura
Villar Taibo, Rocío
Araujo Castro, Marta
Blanco, Concepción
Simón, Inmaculada
Simó Servat, Andreu
Xifra, Gemma
Vázquez, Federico
Pavón, Isabel
García Centeno, Rogelio
Zavala, Roxana
Hanzu, Felicia A.
Mora, Mireia
Aulinas, Anna
Vilarrasa, Nuria
Librizzi, Soledad
Calatayud, María
De Miguel, Paz
Álvarez Escolá, Cristina
Picó, Antonio
Sampedro, Miguel
Salinas, Isabel
Fajardo Montañana, Carmen
Cámara, Rosa
Bernabéu, Ignacio
Jordà, Mireia
Webb, Susan M.
Marazuela, Mónica
Puig Domingo, Manuel
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Acromegàlia
Somatostatina
Acromegaly
Somatostatin
topic Acromegàlia
Somatostatina
Acromegaly
Somatostatin
description Introduction: We previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ultra-sensitive GH assays. We also studied the correlation of sAOT with tumor expression of E-cadherin and somatostatin receptor 2 (SSTR2) .Methods: A total of 47 patients treated with SRLs for 6 months were evaluated with the sAOT at diagnosis and correlated with SRLs' response. Those patients whose IGF1 decreased to <3SDS from normal value were considered responders and those whose IGF1 was >= 3SDS, were considered non-responders. The 2 hours GH value (GH2h) after s.c. administration of 100 mcg of octreotide was used to define predictive cutoffs. E-cadherin and SSTR2 immunostaining in somatotropinoma tissue were investigated in 24/47 and 18/47 patients, respectively.Results: In all, 30 patients were responders and 17 were non-responders. GH(2h) was 0.68 (0.25-1.98) ng/mL in responders vs 2.35 (1.59-9.37) ng/mL in non-responders (p<0.001). GH(2h) = 1.4ng/mL showed the highest ability to identify responders (accuracy of 81%, sensitivity of 73.3%, and specificity of 94.1%). GH(2h) = 4.3ng/mL was the best cutoff for non-response prediction (accuracy of 74%, sensitivity of 35.3%, and specificity of 96.7%). Patients with E-cadherin-positive tumors showed a lower GH(2h) than those with E-cadherin-negative tumors [0.9 (0.3-2.1) vs 3.3 (1.5-12.1) ng/mL; p<0.01], and patients with positive E-cadherin presented a higher score of SSTR2 (7.5 +/- 4.2 vs 3.3 +/- 2.1; p=0.01).Conclusion: The sAOT is a good predictor tool for assessing response to SRLs and correlates with tumor E-cadherin and SSTR2 expression. Thus, it can be useful in clinical practice for therapeutic decision-making in patients with acromegaly.
publishDate 2023
dc.date.none.fl_str_mv 2023
2024
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/205747
url https://hdl.handle.net/2445/205747
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3389/fendo.2023.1269787
Frontiers in Endocrinology, 2023, vol. 14
https://doi.org/10.3389/fendo.2023.1269787
dc.rights.none.fl_str_mv cc by (c) Marques Pamies, Montserrat et al., 2023
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Marques Pamies, Montserrat et al., 2023
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 11 p.
application/pdf
dc.publisher.none.fl_str_mv Frontiers Media SA
publisher.none.fl_str_mv Frontiers Media SA
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404229578260480
score 15,228081

Registos relacionados